AUTHORS
Lara Figorelle, MD, Kurt Bantilan, MPH2, Matthew J Matasar, MD, MS3, Ariela Noy, MD4, Maria Lia Palomba, MD5, David Straus, MD6, Carol Portlock, MD7, Paul Hamlin, MD8, Craig Moskowitz, MD9, Connie Batlevi, MD10, Anita Kumar, MD11, Peter Maslak, MD12, Pamela Drullinsky, MD13, Lorenzo Falchi, MD14, Colette Owens, MD15, Gilles Salles I, MD, PhD16, Pallavi Kanwar Galera, MBBS17, Robert Lee, MD18, Andrew Zelenetz, MD19
AFFILIATIONS
1 Memorial Sloan Kettering Cancer Center, New York, New York, United States
2 Memorial Sloan Kettering Cancer Center, New York, New York, United States
3 Rutgers Cancer Institute of New Jersey, New Brunswick, New Jersey, United States
4 Memorial Sloan Kettering Cancer Center, New York, New York, United States
5 Memorial Sloan Kettering Cancer Center, New York, New York, United States
6 Memorial Sloan Kettering Cancer Center, New York, New York, United States
7 Memorial Sloan Kettering Cancer Center, New York, New York, United States
8 Memorial Sloan Kettering Cancer Center, New York, New York, United States
9 University of Miami Health System, Miami, Florida, United States
10 Memorial Sloan Kettering Cancer Center, New York, New York, United States
11 Memorial Sloan Kettering Cancer Center, New York, New York, United States
12 Roswell Park Comprehensive Cancer Center, Buffalo, New York, United States
13 Memorial Sloan Kettering Cancer Center, New York, New York, United States
14 Memorial Sloan Kettering Cancer Center, New York, New York, United States
15 Memorial Sloan Kettering Cancer Center, New York, New York, United States
16 Memorial Sloan Kettering Cancer Center, New York, New York, United States
17 Memorial Sloan Kettering Cancer Center, New York, New York, United States
18 Memorial Sloan Kettering Cancer Center, New York, New York, United States
19 Memorial Sloan Kettering Cancer Center, New York, New York, United States
ABSTRACT
BACKGROUND:
Although sarcoidosis following non-Hodgkin lymphoma (NHL) has been previously reported, the natural history of these sarcoid-like reactions in the setting of prior NHL has not been well established. Given both sarcoidosis and lymphoma are fluorodeoxyglucose-avid diseases, differentiating between these entities is a challenge. This retrospective study aims to describe and analyze the clinical characteristics, disease status, therapeutic management, and events associated with the diagnosis of sarcoidosis following NHL.
PATIENTS AND METHODS:
We retrospectively identified patients with noncaseating granuloma on biopsy in the clinical setting consistent with sarcoidosis or sarcoid-like reaction following a diagnosis of NHL at Memorial Sloan Kettering between January 1, 1995 to June 1, 2024. Patient demographics and clinical data were abstracted from institutional electronic medical records and a descriptive analysis was performed.
RESULTS:
A total of 58 patients with sarcoidosis or sarcoid-like reaction in the setting of prior NHL were included in this series. The median age at diagnosis was 55 years for NHL and 58 years for sarcoidosis. Thirty-four patients (59%) were asymptomatic, 8 (14%) had B-symptoms, and 16 (28%) had other symptoms (e.g. fatigue, cough). The reason for biopsy was usually abnormal imaging (93%). Sarcoid biopsy sites included only pulmonary nodes in 17 patients (29%), exclusively extra-pulmonary nodes in 5 patients (9%), and both pulmonary and extra-pulmonary nodes in 36 patients (62%).
Sarcoidosis was diagnosed at a median of 23 months after NHL, including 35 of 58 (60%) with no evidence of NHL, 15 (26%) with stable NHL, 4 (7%) with progressive NHL, and 4 (7%) with associated diagnosis of secondary malignancy. At a median follow-up of 14.2 years (95% CI: 9.6 – 20.2), there were 26 NHL progressions and sarcoid was present in association with 4 (15%) of them.
Only 18 of 58 patients (31%) required treatment for sarcoidosis: sarcoid was treated in 2 of 17 (12%) with only pulmonary localization, 3 of 5 (60%) with exclusively extra-pulmonary localization, and 13 of 36 (36%) with both pulmonary and extra-pulmonary involvement. Sarcoid and NHL were co-localized in 18 of 58 patients (31%), with 8 of these 18 (44%) needing treatment for sarcoid. Of the 18 treated for sarcoid, 10 (56%) were treated only with systemic corticosteroids, 3 (17%) with systemic and topical corticosteroids, 3 (17%) with systemic corticosteroids and other agents (e.g. methotrexate, rituximab, hydroxychloroquine), and 2 (11%) with only hydroxychloroquine.
Forty-six of the total 58 patients (79%) had received systemic chemotherapy for NHL prior to sarcoid, with a median time from first chemotherapy to sarcoid diagnosis of 24 months. Among these 46 patients, 33 (72%) received 1 line of chemotherapy, 11 (24%) received 2 lines, 1 (2%) received 3 lines, and 1 (2%) received 4 lines.
Procedural diagnostics for sarcoid changed over the decades. Surgical biopsies (SB) were more common in the 1990s (SB 100%) and 2000s (SB 94%; endobronchial ultrasound-guided transbronchial needle aspiration [EBUS TBNA] 6%). These steadily declined and were replaced by an increasing number of EBUS TBNA and interventional radiology-guided biopsies (IR) in the 2010s (SB 29%; EBUS TBNA 29%; IR 43%) and 2020s (SB 7%; EBUS TBNA 53%; IR 40%).
DISCUSSION:
In this series of patients with prior NHL, sarcoidosis with only pulmonary localization were less likely to require treatment compared to those with exclusively extra-pulmonary involvement. This pattern is similar to what is seen with conventional systemic sarcoidosis. Most patients had received chemotherapy for NHL prior to the diagnosis of sarcoidosis, which would support the hypothesis that sarcoidosis in this setting may represent a side effect of chemotherapy. Most patients (60%) had no evidence of NHL when sarcoidosis was diagnosed, and sarcoidosis was present in association with only 15% of NHL progressions. This suggests that sarcoidosis in patients with prior NHL may represent a distinct entity rather than an immune or inflammatory reaction to active malignancy. Given the similar presentation and radiographic findings in recurrent NHL and sarcoidosis, it is important to consider sarcoidosis in the differential diagnosis of any potential progression event, and a biopsy should be obtained.
DISCLOSURES
Lara Figorelle, MD: No relevant conflicts of interest to declare.